236 related articles for article (PubMed ID: 9234682)
1. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy.
Bontron S; Ucla C; Mach B; Steimle V
Mol Cell Biol; 1997 Aug; 17(8):4249-58. PubMed ID: 9234682
[TBL] [Abstract][Full Text] [Related]
2. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
[TBL] [Abstract][Full Text] [Related]
3. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.
Liu A; Takahashi M; Toba K; Zheng Z; Hashimoto S; Nikkuni K; Furukawa T; Koike T; Aizawa Y
Hematol Oncol; 1999 Dec; 17(4):149-60. PubMed ID: 10725870
[TBL] [Abstract][Full Text] [Related]
5. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.
Hake SB; Masternak K; Kammerbauer C; Janzen C; Reith W; Steimle V
Mol Cell Biol; 2000 Oct; 20(20):7716-25. PubMed ID: 11003667
[TBL] [Abstract][Full Text] [Related]
6. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain.
Yun S; Gustafsson K; Fabre JW
Transplantation; 1998 Jul; 66(1):103-11. PubMed ID: 9679829
[TBL] [Abstract][Full Text] [Related]
7. Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene.
Peijnenburg A; Van den Berg R; Van Eggermond MJ; Sanal O; Vossen JM; Lennon AM; Alcaïde-Loridan C; Van den Elsen PJ
Immunogenetics; 2000 Jan; 51(1):42-9. PubMed ID: 10663561
[TBL] [Abstract][Full Text] [Related]
8. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants.
Chin KC; Li GG; Ting JP
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2501-6. PubMed ID: 9122224
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells.
Butticè G; Miller J; Wang L; Smith BD
Circ Res; 2006 Mar; 98(4):472-9. PubMed ID: 16439692
[TBL] [Abstract][Full Text] [Related]
10. Structural and functional characteristics of a dominant-negative isoform of porcine MHC class II transactivator.
Quinn G; Bower R; Dos-Santos Cruz G; Giovino M; Xu Y; Patience C; Schuurman HJ
Eur J Immunogenet; 2003 Aug; 30(4):259-70. PubMed ID: 12919287
[TBL] [Abstract][Full Text] [Related]
11. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.
Steimle V; Siegrist CA; Mottet A; Lisowska-Grospierre B; Mach B
Science; 1994 Jul; 265(5168):106-9. PubMed ID: 8016643
[TBL] [Abstract][Full Text] [Related]
12. Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression.
Zika E; Fauquier L; Vandel L; Ting JP
Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16321-6. PubMed ID: 16254053
[TBL] [Abstract][Full Text] [Related]
13. IL-1 beta inhibits IFN-gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene.
Rohn W; Tang LP; Dong Y; Benveniste EN
J Immunol; 1999 Jan; 162(2):886-96. PubMed ID: 9916712
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.
Kanaseki T; Ikeda H; Takamura Y; Toyota M; Hirohashi Y; Tokino T; Himi T; Sato N
J Immunol; 2003 May; 170(10):4980-5. PubMed ID: 12734341
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction.
Chin KC; Mao C; Skinner C; Riley JL; Wright KL; Moreno CS; Stark GR; Boss JM; Ting JP
Immunity; 1994 Nov; 1(8):687-97. PubMed ID: 7600294
[TBL] [Abstract][Full Text] [Related]
16. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells.
Kwak B; Mulhaupt F; Veillard N; Pelli G; Mach F
Swiss Med Wkly; 2001 Jan; 131(3-4):41-6. PubMed ID: 11219190
[TBL] [Abstract][Full Text] [Related]
17. Degradation, Promoter Recruitment and Transactivation Mediated by the Extreme N-Terminus of MHC Class II Transactivator CIITA Isoform III.
Beaulieu YB; Leon Machado JA; Ethier S; Gaudreau L; Steimle V
PLoS One; 2016; 11(2):e0148753. PubMed ID: 26871568
[TBL] [Abstract][Full Text] [Related]
18. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class IL transactivator CIITA in class II non-inducible RB-defective tumor lines.
Tschickardt ME; Lu Y; Jacim M; Ussery GD; Steimle V; Mach B; Blanck G
Int J Cancer; 1995 Aug; 62(4):461-5. PubMed ID: 7635572
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.
Zika E; Greer SF; Zhu XS; Ting JP
Mol Cell Biol; 2003 May; 23(9):3091-102. PubMed ID: 12697811
[TBL] [Abstract][Full Text] [Related]
20. Suppression of MHC class II expression by human class II trans-activator constructs lacking the N-terminal domain.
Yun S; Gustafsson K; Fabre JW
Int Immunol; 1997 Oct; 9(10):1545-53. PubMed ID: 9352360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
